摘要
目的:观察乙酰半胱氨酸联合头孢哌酮钠舒巴坦钠治疗慢性阻塞性肺疾病(COPD)合并肺部感染患者的效果。方法:选取2021年1月至2023年1月该院收治的80例COPD合并肺部感染患者进行前瞻性研究,按照随机数字表法将其分为研究组与对照组各40例,对照组采用头孢哌酮钠舒巴坦钠治疗,研究组在对照组基础上联合乙酰半胱氨酸片治疗。比较两组临床疗效,治疗前后炎性因子[C反应蛋白(CRP)、白细胞介素-6(IL-6)、降钙素原(PCT)]、肺功能指标[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、气道峰压(PIP)、每分通气量(MV)]、血气分析指标[动脉血二氧化碳分压(PaCO_(2))、动脉血氧饱和度(SaO_(2))、动脉血氧分压(PaO_(2))]水平,以及不良反应发生率。结果:研究组治疗总有效率为95.00%(38/40),高于对照组的77.50%(31/40),差异有统计学意义(P<0.05);治疗后,两组PCT、CRP、IL-6水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组FEV1、FVC、MV、PIP水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);治疗后,两组PaCO_(2)水平均低于治疗前,且研究组低于对照组,两组PaO_(2)、SaO_(2)水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:乙酰半胱氨酸联合头孢哌酮钠舒巴坦钠治疗COPD合并肺部感染患者可提高治疗总有效率和肺功能指标水平,改善血气分析指标水平,降低炎性因子水平,其效果优于单纯头孢哌酮钠舒巴坦钠治疗。
Objective:To observe effects of Acetylcysteine combined with Sulbactam and Cefoperazone sodium in treatment of patients with chronic obstructive pulmonary disease(COPD)complicated with pulmonary infection.Methods:A prospective study was conducted on 80 patients with COPD complicated with pulmonary infection admitted to the hospital from January 2021 to January 2023.According to the random number table method,they were divided into study group and control group,40 cases in each group.The control group was treated with Sulbactam and Cefoperazone sodium,while the study group was treated with Acetylcysteine tablets on the basis of that of the control group.The clinical efficacy,the levels of inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6),procalcitonin(PCT)],lung function indexes[forced expiratory volume in one second(FEV1),forced vital capacity(FVC),peak inspiratory pressure(PIP),minute ventilation(MV)]and blood gas analysis indexes[arterial partial pressure of carbon dioxide(PaCO_(2)),arterial oxygen saturation(SaO_(2)),arterial partial pressure of oxygen(PaO_(2))]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 95.00%(38/40),which was higher than 77.50%(31/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of PCT,CRP and IL-6 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of FEV1,FVC,MV and PIP in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,the and differences were statistically significant(P<0.05).After the treatment,the PaCO_(2)levels of the two groups were lower than those before the treatment,and that in the study group was lower than that in the control group;the levels
作者
刘英慧
刘小庆
LIU Yinghui;LIU Xiaoqing(Jingbian County People’s Hospital,1.Department of Comprehensive Internal Medicine,2.Infectious Disease Department,Yulin 718500 Shaanxi,China)
出处
《中国民康医学》
2024年第18期27-30,共4页
Medical Journal of Chinese People’s Health
关键词
乙酰半胱氨酸
头孢哌酮钠舒巴坦钠
慢性阻塞性肺疾病
肺部感染
肺功能
血气分析指标
炎性因子
Acetylcysteine
Sulbactam and Cefoperazone sodium
Chronic obstructive pulmonary disease
Pulmonary infection
Lung function
Blood gas analysis index
Inflammatory factor
